| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1040-8428(00)00129-3 |
| P698 | PubMed publication ID | 11578916 |
| P2093 | author name string | de Leij LF | |
| Harmsen MC | |||
| Kroesen BJ | |||
| McLaughlin PM | |||
| P2860 | cites work | The threshold for autoimmune T cell killing is influenced by B7-1 | Q57228048 |
| The distribution of PSA, cathepsin‐D, and pS2 in BPH and cancer of the prostate | Q67464053 | ||
| Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance | Q67657717 | ||
| Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance | Q67705312 | ||
| An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours | Q68070513 | ||
| Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet beta cells | Q68111034 | ||
| Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide | Q68680881 | ||
| Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen | Q68976823 | ||
| Expression and function of HLA-A2.1 in transgenic mice | Q69541349 | ||
| A rat lung cancer model based on intrapulmonary implantation of tumour material | Q69601186 | ||
| The occurrence of mouse-type oligosaccharides in mouse-human chimeric immunoglobulin G | Q69772666 | ||
| Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody | Q70214742 | ||
| Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice | Q70911259 | ||
| Skin allograft rejection in CD28-deficient mice | Q71023130 | ||
| The fate of adoptively transferred antigen-specific T cells in vivo | Q71548698 | ||
| Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies | Q71564563 | ||
| Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model | Q72333420 | ||
| Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes | Q72687662 | ||
| IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer | Q73091523 | ||
| High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999) | Q73270668 | ||
| Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy | Q73486646 | ||
| Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product | Q73798468 | ||
| Human IgG Fc Receptors | Q74747966 | ||
| Targeting tumor cells with bispecific antibodies and T cells | Q77314476 | ||
| The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection | Q77714923 | ||
| Genetic immunization against neu/erbB2 transgenic breast cancer | Q77754410 | ||
| The use of human leucocyte antigen class I transgenic mice to investigate human immune function | Q77813558 | ||
| Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice | Q77959313 | ||
| CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors | Q78032780 | ||
| Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes | Q43470250 | ||
| A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics | Q43873627 | ||
| Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope | Q44020572 | ||
| Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors | Q45856066 | ||
| Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα | Q45885022 | ||
| Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. | Q46430404 | ||
| The coming of age of tumour immunotherapy | Q47603527 | ||
| γ-Ray irradiation induces B7.1 costimulatory molecule neoexpression in various murine tumor cells | Q47741619 | ||
| Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice | Q50800754 | ||
| Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial | Q50888945 | ||
| Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors | Q52061501 | ||
| Selection of highly transfectable variant from mouse mastocytoma P815. | Q52833961 | ||
| Clonal deletion of thymocytes as a tumor escape mechanism | Q54123346 | ||
| Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins | Q24309815 | ||
| Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression | Q24599825 | ||
| DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES | Q24679675 | ||
| The biology of the 17-1A antigen (Ep-CAM) | Q28140874 | ||
| The Immunogenic Properties of Melanoma-Associated Antigens Recognized by Cytotoxic T Lymphocytes | Q28273125 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 | ||
| A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse | Q29616489 | ||
| Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene | Q29616490 | ||
| The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice | Q30304846 | ||
| Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice | Q30464031 | ||
| A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments | Q30657795 | ||
| A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) | Q33349721 | ||
| Cancer control in susceptible groups: opportunities and challenges | Q33542060 | ||
| Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials | Q33542522 | ||
| Advances in cancer immunotherapy | Q33546850 | ||
| T cell tolerance to Mlsa encoded antigens in T cell receptor V beta 8.1 chain transgenic mice. | Q33560835 | ||
| Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. | Q33570816 | ||
| Advances in cancer vaccine development | Q33603404 | ||
| Targeting p53 as a general tumor antigen | Q33638172 | ||
| Insights into cancer from transgenic mouse models | Q33643327 | ||
| Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. | Q33681148 | ||
| Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy | Q33699292 | ||
| Cancer gene and immunotherapy: recent developments | Q33717186 | ||
| How tumors escape immune destruction and what we can do about it. | Q33740958 | ||
| Recombinant antibody constructs in cancer therapy | Q33745179 | ||
| Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism | Q33797447 | ||
| Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation | Q33807284 | ||
| Progress in active specific immunotherapy of prostate cancer | Q33807301 | ||
| The HLA crossroad in tumor immunology | Q33829869 | ||
| Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes | Q34274059 | ||
| Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group | Q34322325 | ||
| Prostate cancer in a transgenic mouse | Q34444393 | ||
| HLA polymorphisms and evolution | Q35273813 | ||
| Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors | Q35525622 | ||
| Human prostate-specific antigen: structural and functional similarity with serine proteases | Q35604260 | ||
| Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine | Q35750646 | ||
| Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy | Q35755567 | ||
| Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix | Q35787787 | ||
| Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. | Q36079746 | ||
| Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy | Q36184573 | ||
| Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | Q36301801 | ||
| Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo | Q36367135 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. | Q36376876 | ||
| Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level | Q36404676 | ||
| Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression | Q36600110 | ||
| Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models | Q36660661 | ||
| Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy | Q36772676 | ||
| Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. | Q36780750 | ||
| B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28 | Q36851775 | ||
| Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice | Q37350204 | ||
| Induction of Primary,Human Antigen-Specific Cytotoxic T Lymphocytes In Vitro Using Dendritic Cells Pulsed with Peptides | Q38340280 | ||
| Genetic epidemiology of Greenland | Q38738759 | ||
| Epithelial mucin genes | Q40543275 | ||
| Molecular cloning and expression of carcinoembryonic antigen gene family members. | Q40597487 | ||
| Carcinoembryonic antigen-transgenic mice: a model for tumor immunotherapy. | Q40597516 | ||
| Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. | Q40711132 | ||
| Tumor necrosis factor: a pleiotropic cytokine and therapeutic target | Q40759728 | ||
| A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity | Q40925786 | ||
| Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer | Q40928916 | ||
| An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy | Q40931234 | ||
| Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis | Q40935117 | ||
| Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. | Q40987400 | ||
| An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice | Q41055226 | ||
| Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRI×murine MHC class II bispecific antibody | Q41070903 | ||
| Transgenesis in rats: technical aspects and models | Q41074600 | ||
| Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-alpha and transforming growth factor-beta mRNA production | Q41082432 | ||
| The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. | Q41111519 | ||
| Cytokine therapy of malignant melanoma | Q41114754 | ||
| Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). | Q41122596 | ||
| Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes | Q41187464 | ||
| Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine | Q41327004 | ||
| Implications for immunosurveillance of altered HLA class I phenotypes in human tumours | Q41370602 | ||
| The role of FasL-induced apoptosis in immune privilege | Q41472346 | ||
| Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. | Q41500979 | ||
| The Emerging Role of CTLA-4 as an Immune Attenuator | Q41630509 | ||
| Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen | Q41702336 | ||
| Generation of human monoclonal antibodies against colon cancer | Q41712061 | ||
| Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo | Q41953353 | ||
| Establishment and characterisation of human carcinoembryonic antigen transgenic mice | Q42281531 | ||
| Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice | Q42816977 | ||
| Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex | Q42941471 | ||
| P433 | issue | 1 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 53-76 | |
| P577 | publication date | 2001-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Cancer immunotherapy: insights from transgenic animal models | |
| P478 | volume | 40 |
| Q80510580 | AIDS-associated malignancies |
| Q81449950 | EpCAM homologues exhibit epithelial-specific but different expression patterns in the kidney |
| Q58696260 | Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope |
| Q33807710 | RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule |
| Q35868868 | Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors |
| Q36909378 | T-cell receptor gene therapy for cancer: the progress to date and future objectives |
Search more.